PLSE — Pulse Biosciences, Inc.

Pulse Biosciences (PLSE) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $86,000, marking the company's initial revenue from nPulse capital and Vybrance disposable sales.
• GAAP Net Loss: $19.4 million, up from $12.7 million in Q3 2024.
• Non-GAAP Net Loss: $13.5 million, compared to $9.4 million in the prior year.
• Total GAAP Costs and Expenses: Increased to $20.5 million from $13.7 million, primarily due to rising operational costs and noncash stock-based compensation ($5.6 million).
• Cash Position: $95.2 million as of September 30, 2025, down $11.1 million from Q2 2025, with cash used in operations increasing to $13 million.

2. Strategic Updates and Business Highlights

• Product Development:
  • Launched the nPulse Vybrance percutaneous electrode system for soft tissue ablation, with over 200 patients treated.
  • Received FDA approval for the IDE pivotal study of the nPulse surgical ablation clamp for atrial fibrillation (AF).
  • Initiated the PRECISE-BTN clinical study for benign thyroid nodule treatment.
• Market Adoption: Positive early outcomes and increasing procedure volumes reported, with physicians expressing satisfaction with the Vybrance procedure's safety and effectiveness.
• Regulatory Progress: Advancements in IDE submissions for the nPulse 360 Catheter, with expectations to commence studies in Q1 2026.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated growth in disposables and full system sales as procedure acceptance increases. The company is focused on building a viable organization for long-term success.
• Expense Management: Expected increase in quarterly cash use due to ongoing clinical trials and commercialization efforts.
• Market Expansion: Plans to maintain current commercial headcount while expanding into new geographies once initial accounts achieve desired utilization levels.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The significant rise in net losses and operational costs raises concerns about the sustainability of current spending levels.
• Cash Burn: Continued cash burn may necessitate future fundraising or strategic partnerships to support ongoing clinical trials and commercialization efforts.
• Regulatory Risks: While progress has been made, the company faces inherent risks associated with regulatory approvals and clinical trial outcomes.

5. Notable Q&A Insights

• Clinical Trial Design: Clarification on the NANOCLAMP trial indicated that lesion sets vary based on AF severity, with discretion given to surgeons.
• Funding Strategy: The company plans to fund the nPulse 360 Catheter pivotal trial independently, while remaining open to potential partnerships for commercialization.
• Performance Metrics for PRECISE-BTN: Emphasis on establishing a composite endpoint for patient outcomes, including quality of life and volume reduction, rather than relying solely on symptom elimination.

Overall, Pulse Biosciences is making significant strides in product development and market adoption, although it faces challenges related to increasing losses and cash burn. The company's focus on strategic partnerships and regulatory progress will be crucial as it moves forward.